Arca
Skip to content
Tools
Tools

Primitive neuroectodermal tumor

Drug research and approvals for primitive neuroectodermal tumor: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 141 studies of primitive neuroectodermal tumor are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.

  • Recruiting worldwide: 141
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 141 recruiting on ClinicalTrials.gov ↗

How its trials ended

142 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 32 whose ending is known, 28% met their primary endpoint, 19% missed it and 53% stopped early.

  • Completed, result not reported7351%
  • Ongoing3021%
  • Met its primary endpoint96%
  • Stopped: other or unclear96%
  • Status unknown75%
  • Missed its primary endpoint64%
  • Stopped: enrollment or feasibility54%
  • Stopped: lack of efficacy21%
  • Stopped: sponsor or business decision11%

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.